VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
OMRON Corporation vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
OMRON Corporation
6645 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into OMRON Corporation's moat claims, evidence, and risks.
View 6645 analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: OMRON Corporation leads (59 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: OMRON Corporation has 5 segments (45% in Industrial Automation Business (IAB)); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Moat breadth: OMRON Corporation has 7 moat types across 4 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
OMRON Corporation
Industrial Automation Business (IAB)
Industrial automation components and factory automation solutions (sensors, controllers, safety, robotics, OT/IT services)
Global
Manufacturers and machine builders (B2B)
Automation supplier + solutions/services provider
45%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
OMRON Corporation strengths
Bristol-Myers Squibb Company strengths
Segment mix
OMRON Corporation segments
Full profile >Industrial Automation Business (IAB)
Oligopoly
Healthcare Business (HCB)
Competitive
Social Systems, Solutions and Service Business (SSB)
Oligopoly
Device and Module Solutions Business (DMB)
Competitive
Data Solution Business (DSB)
Oligopoly
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.